Royalty Pharma plc [RPRX] is 6.80% higher this YTD. Is it still time to buy?


Royalty Pharma plc [NASDAQ: RPRX] plunged by -$0.27 during the normal trading session on Tuesday and reaching a high of $43.14 during the day while it closed the day at $42.56. The company report on June 8, 2022 that Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at The webcast will also be archived for a minimum of thirty days.

Royalty Pharma plc stock has also gained 6.11% of its value over the past 7 days. However, RPRX stock has inclined by 12.03% in the 3 months of the year. Over the past six months meanwhile, it has gained 6.06% and gained 6.80% year-on date.

The market cap for RPRX stock reached $24.57 billion, with 433.96 million shares outstanding and 196.09 million shares in the current float. Compared to the average trading volume of 2.44M shares, RPRX reached a trading volume of 4036789 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Royalty Pharma plc [RPRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RPRX shares is $52.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RPRX stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

UBS have made an estimate for Royalty Pharma plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 14, 2022. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 13, 2022, representing the official price target for Royalty Pharma plc stock. Previously, the target price had yet another raise to $56, while Goldman analysts kept a Buy rating on RPRX stock.

The Average True Range (ATR) for Royalty Pharma plc is set at 1.21, with the Price to Sales ratio for RPRX stock in the period of the last 12 months amounting to 10.78. The Price to Book ratio for the last quarter was 3.20, with the Price to Cash per share for the same quarter was set at 5.04.

RPRX stock trade performance evaluation

Royalty Pharma plc [RPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.11. With this latest performance, RPRX shares gained by 6.37% in over the last four-week period, additionally plugging by 6.06% over the last 6 months – not to mention a rise of 1.58% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RPRX stock in for the last two-week period is set at 60.97, with the RSI for the last a single of trading hit 65.54, and the three-weeks RSI is set at 58.03 for Royalty Pharma plc [RPRX]. The present Moving Average for the last 50 days of trading for this stock 40.92, while it was recorded at 41.90 for the last single week of trading, and 39.51 for the last 200 days.

Royalty Pharma plc [RPRX]: An insightful look at the core fundamentals

Royalty Pharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 22.00 and a Current Ratio set at 22.00.

Earnings per share (EPS) analysis for Royalty Pharma plc [RPRX] stock

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RPRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Royalty Pharma plc go to 11.20%.

Royalty Pharma plc [RPRX]: Insider Ownership positions

There are presently around $11,587 million, or 63.10% of RPRX stock, in the hands of institutional investors. The top three institutional holders of RPRX stocks are: MORGAN STANLEY with ownership of 53,541,788, which is approximately -4.782% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 31,860,621 shares of the stock with an approximate value of $1.36 billion in RPRX stocks shares; and FMR LLC, currently with $1.21 billion in RPRX stock with ownership of nearly 27.742% of the company’s market capitalization.

178 institutional holders increased their position in Royalty Pharma plc [NASDAQ:RPRX] by around 23,151,377 shares. Additionally, 98 investors decreased positions by around 20,045,294 shares, while 34 investors held positions by with 227,329,254 shares. The mentioned changes placed institutional holdings at 270,525,925 shares, according to the latest SEC report filing. RPRX stock had 50 new institutional investments in for a total of 5,080,230 shares, while 36 institutional investors sold positions of 4,512,532 shares during the same period.